SNY Stock Analysis: Buy, Sell, or Hold?
SNY - Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
$41.33
-0.27 (-0.65%)
▼
5d:
-6.17%
30d:
-6.68%
90d:
-8.44%
HOLD
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Get Alerted When SNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SNY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: SNY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$59.66
Based on 5.1% avg growth
INTRINSIC VALUE TODAY
$37.04
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNY is currently trading at $41.33, which is considered oversold relative to its 30-day fair value range of $42.59 to $44.59. From a valuation perspective, the stock is trading at a discount (Forward PE: 7.9) compared to its historical average (8.8). Remarkably, the market is currently pricing in an annual earnings decline of 3.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SNY is in a strong downtrend. The price is currently testing key support at $40.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNY has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $55.90 (+34.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SNY is in a strong downtrend. The price is currently testing key support at $40.89. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNY has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $55.90 (+34.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$42.59 -
$44.59
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.4% below Wall St target ($55.90)
- CAUTION: 5-day price weakness (-6.2%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$42.59 -
$44.59
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$40.89
Resistance Level
$44.55
Current Trend
Strong Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.87
Wall Street Target
$55.90
(+34.4%)
Revenue Growth (YoY)
6.0%
Earnings Growth (YoY)
-11.7%
Profit Margin
16.0%
Valuation Discount vs History
-3.6% cheaper
PE vs Historical
7.9 vs 8.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.6%
(market-implied from PE analysis)
1-Year Target
$40.10
(-4%)
2-Year Target
$38.66
(-7%)
3-Year Target
$37.27
(-10%)
3-Yr Target (if PE normalizes)
(PE: 8→9)
$41.68
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 6.2%)
$137.87
(+231%)
Base:
(SPY PE: 7.9, Growth: 6.2%)
$49.80
(+20%)
Bear:
(PE: 6.7, Growth: 6.2%)
$42.33
(+2%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 18.41 | Current EPS (TTM): $2.27
Bull Case
$91.92
(+121%)
Analyst growth 100.0%, PE expands to 20.3
Base Case
$83.56
(+101%)
Market implied 100.0%, PE stable at 18.4
Bear Case
$28.41
(-32%)
Severe decline -20.0%, PE contracts to 15.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.9 to 8.8
Stabilization Target:
$46.53
(+11.8%)
PE Expansion Potential:
+11.8%
Share & Embed Analysis
Last updated: June 24, 2026 4:44 PM ET
Data refreshes hourly during market hours. Next update: 5:44 PM
Data refreshes hourly during market hours. Next update: 5:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1219 | 52 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 61 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 65 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 62 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 62 BUY |
